Efficacy And Safety Of Imatinib Mesylate For Treating Patients With Chronic Myeloid Leukemia In Chronic Phase

Objective: To evaluate the early hematologic,cytogenetic,molecular responses and security in newly diagnonosed patients with chronic myeloid leukemia in chronic phase(CML-CP)who were initially treated with imatinib mesylate.Methods: 28 newly diagonosed CML-CP patients who aged above 18 years old and never received other drugs for CML except hydroxyurea were recruited,10 of them were treated with imported imatinib and 18 of them were treated with domestic imatinib 400 mg QD oral initially according to their intensions.Evaluate the hematological response,cytogenetic and molecular biological response at 3 months,6 months and 12 months,and side effects of drugs throughout the study.Results: 1.The resultes showed that at 3 months,all the patient of two groups received complete hematological response.2.The complete cytogenetic response at 3 months,6 months and 12 months of Glivec and domestic imatinib were 80%(8/10)vs 50%(9/18),80 %(8/10)vs 61.11%(11/18),88.89%(8/9)vs 70.59%(12/17),the difference was not statistically significant.3.The major molecular response at 3 months,6 months and 12 months of Glivec and domestic imatinib group were respectively 20%(2/10)vs 16.67%(3/18)and 60%(6/10)vs 44.44%(8/18),77.78%(7/9)vs 52.94%(9/17),the difference was not statistically significant.4.Domestic drug was well tolerated,and the side efeects were similar between two groups.Conclusion: The study showed that imatinib mesylate has significant effects and good security for CML-CP patients.Early hematological,cytogenetic,molecular responses and side effects between Glivec and domestic imatinib are comparable in newly diagnosed CML-CP patients.